- Active Pharma Ingredients (API)
- Custom Pharma Services (CPS)
- Generics
- Generic Biopharmaceuticals
- NCEs & Differentiated Formulations
- New Chemical Entities (NCEs)
- Contact Us
- Promius Pharma Launches Promiseb™ Cream
July 29, 2009 - Promius Pharma, LLC Launches Scytra™ (Coal Tar) Foam 2% for treatment of psoriasis
January, 2009 - Promius Pharma launches EPICERAM® skin barrier emulsion
October 14, 2008 - Dr. Reddy's announces its US Specialty Business, Promius Pharma, LLC
September 18, 2008
Promiseb™ Topical Cream
Promiseb™ is contraindicated in persons with a known hypersensitivity to any component of the formulation. Please see accompanying important safety information and full prescribing info. For more info, visit www.Promiseb.com. Promiseb™ does not contain milk, wheat, peanut or animal derivatives. This Cream does contain shea butter (Butyrospermum parkii), a derivative of shea nut oil (not peanut oil). Patients with a known allergy to nuts or nut oils should consult their physician before using this topical preparation.
Scytera Foam
Scytera Foam is a novel coal tar foam for the treatment of psoriasis, a skin disease that affects approximately 7.5 million Americans according to the National Psoriasis Foundation. Scytera Foam delivers a time tested active ingredient, coal tar, in a cosmetically elegant foam formulation. Please visit www.scytera.com for more information about Scytera Foam, including usage instructions.
EpiCeram® Skin Barrier Emulsion
EpiCeram® Skin Barrier Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million patients in the United States. EpiCeram was developed to specifically address the defective skin barrier of atopic patients to safely and effectively control the signs and symptoms of atopic dermatitis. Please visit www.EpiCeram.com for more information about EpiCeram Emulsion, including prescribing information.





